Originally published 2021-12-22.
On 20 December 2021 the US Food and Drug Administration approved Apretude, an injection of the antiretroviral drug cabotegravir, as the first long-acting medicine to prevent HIV. Instead of a pill every day, people at risk of HIV receive two starter injections one month apart and then one injection every two months. In clinical trials it prevented more infections than daily oral PrEP, largely because people do not have to remember a daily tablet.
Apretude is a prevention tool, not a cure or a treatment for people who already have HIV. Here is what it is, how well it works, who it is for and what has happened since.
What PrEP is and why an injection matters
PrEP stands for pre-exposure prophylaxis: taking HIV medicine before possible exposure so the virus cannot establish an infection. Until 2021, PrEP in the US meant daily pills such as Truvada or Descovy. Taken consistently, those pills are highly effective, reducing the risk of getting HIV through sex by about 99%, according to figures cited by NBC News.
The weak point is consistency. Missed doses lower protection, and many people find a daily pill hard to keep up because of busy lives, stigma, privacy concerns at home or unstable housing. A shot every two months, given at a clinic, removes most of that daily burden.
PrEP is different from PEP, post-exposure prophylaxis. PEP is an emergency course of HIV medicine started as soon as possible, and within 72 hours, after a possible exposure, then taken for 28 days.
What the trials found
The FDA based its approval on two large randomised, double-blind trials run by the HIV Prevention Trials Network, which compared cabotegravir injections with daily oral PrEP pills:
- HPTN 083 enrolled cisgender men and transgender women who have sex with men. People receiving the injection had about 69% fewer HIV infections than those on daily pills.
- HPTN 084 enrolled cisgender women in sub-Saharan Africa. The injection group had about 90% fewer infections than the pill group.
Both trials were stopped early because the injection was clearly outperforming the pills. The comparison was against an already effective drug, so these figures show how much better the injection did in real-world use, mainly thanks to better adherence.
The FDA's antivirals director, Dr Debra Birnkrant, said the approval "adds an important tool in the effort to end the HIV epidemic". ViiV Healthcare, the company that makes Apretude, highlighted that the trials enrolled unusually large numbers of transgender women and Black men who have sex with men, groups often underrepresented in research.
Who can use Apretude
Apretude is approved for adults and adolescents weighing at least 35 kg who are at risk of getting HIV through sex. Before starting, and before every injection, a person must test negative for HIV. That rule matters: if someone with an undetected infection receives cabotegravir alone, the virus can develop resistance to an important class of HIV drugs. The label carries a boxed warning on this point.
The most common side effect is pain, swelling or tenderness where the shot is given, in the buttock muscle. Headache, fever, tiredness and nausea are also reported. Like oral PrEP, it does not protect against other sexually transmitted infections.
Whether PrEP, and which kind, is right for someone is a decision to make with a doctor or sexual health clinic.
Cost and access concerns
At launch, the list price was about $3,700 per injection, or more than $22,000 a year. NBC News reported that, unlike oral PrEP pills, insurers were not then required to cover the injection without cost-sharing.
Advocates welcomed the new option but warned that rollout would be slow. Kenyon Farrow of the advocacy group PrEP4All pointed out that public health workforces were exhausted by COVID-19, and that because the injection must be given in a clinic, insurers would treat it as a medical service rather than a pharmacy drug, which requires new billing systems and nurse training.
Access was already uneven. According to CDC figures cited at the time, only about a quarter of the roughly 1.2 million Americans who could benefit from PrEP had been prescribed it. In 2019, gay and bisexual men accounted for about two-thirds of new HIV diagnoses in the US, and Black Americans for about 42%, far above their share of the population.
What has happened since
Long-acting prevention has kept advancing. The World Health Organization added injectable cabotegravir to its HIV prevention guidance in 2022, and the European Union approved it for PrEP in September 2023.
In June 2025 the FDA approved lenacapavir, sold as Yeztugo, the first PrEP given only twice a year. In trials it provided near-complete protection. Its US list price of more than $28,000 a year has again raised questions about who will be able to get it.
Common misunderstandings
"It is an HIV vaccine." No. Apretude is a medicine that must be repeated every two months; protection fades if injections stop. There is still no approved HIV vaccine.
"It cures HIV." No. It only prevents infection in people who are HIV-negative. People living with HIV use different treatment regimens, which now include a separate long-acting injectable combination.
"PrEP means condoms are unnecessary." PrEP prevents HIV, but not syphilis, gonorrhoea or chlamydia, which is why regular sexual health testing remains part of any PrEP programme.
HIV remains a serious global problem, and AIDS-related illnesses have killed tens of millions of people since the epidemic began. Each prevention option that fits a different life makes it more realistic to bring new infections down.
Sources: NBC News: FDA approves first injectable HIV prevention drug; Wikipedia: Cabotegravir; Wikipedia: Pre-exposure prophylaxis for HIV prevention.

COMMENTS